Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 64 results for etanercept

  1. Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors (TA407)

    Evidence-based recommendations on secukinumab (Cosentyx) for treating active ankylosing spondylitis that has not responded well enough to conventional therapy.

    Technology appraisal guidance
    Published
    28 September 2016
    View recommendations

    Sections for TA407

  2. Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]

    Discontinued [GID-TAG393]

    Technology appraisal guidance
    Discontinued

  3. Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)

    Evidence-based recommendations on deucravacitinib for treating moderate to severe plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    28 June 2023
    View recommendations

    Sections for TA907

  4. Upadacitinib for treating moderate rheumatoid arthritis (TA744)

    Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderate active rheumatoid arthritis in adults.

    Technology appraisal guidance
    Published
    10 November 2021
    View recommendations

    Sections for TA744

  5. Tocilizumab for the treatment of systemic juvenile idiopathic arthritis (TA238)

    Evidence-based recommendations on tocilizumab (RoActemra), for treating systemic juvenile idiopathic arthritis in people aged 2 and over.

    Technology appraisal guidance
    Published
    14 December 2011
    View recommendations

    Sections for TA238

  6. Trials that evaluate utility values (using generic preference-based measures) in children and young people with severe psoriasis are needed to better inform future cost–utility analyses.

    Source guidance details Comes from guidance Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young...

    Research recommendation
    Published
    15 October 2018

  7. NICE agreed that further research would be of value to investigate factors which can predict the likelihood of rapid progression of disease and response to treatment with biological DMARDs. Factors to investigate include:- persistent elevation of inflammatory markers (such as C-reactive protein [CRP]) and- presence of erosions on X-ray and- positive for anti-citrullinated protein antibodies (ACPA).

    Source guidance details Comes from guidance Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept

    Research recommendation
    Published
    15 March 2016

  8. Management of inflammatory arthritis

    the most commonly prescribed biological DMARDs, such as adalimumab and etanercept, belong to a class of medicines called anti-tumour...

  9. RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease (MIB109)

    NICE has developed a medtech innovation briefing (MIB) on RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease .

    Medtech innovation briefing
    Published
    20 June 2017

  10. Adalimumab, etanercept and infliximab for ankylosing spondylitis (TA143)

    This guidance has been updated and replaced by NICE technology appraisal guidance 383.

    Technology appraisal guidance
    Published
    28 May 2008

  11. Etanercept and infliximab for the treatment of psoriatic arthritis (TA104)

    This guidance has been replaced by NICE technology appraisal guidance 199.

    Technology appraisal guidance
    Published
    26 July 2006

  12. Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (TA130)

    This guidance has been updated and replaced by NICE technology appraisal guidance 375.

    Technology appraisal guidance
    Published
    22 October 2007

  13. Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis (TA35)

    This guidance has been updated and replaced by NICE technology appraisal guidance 373.

    Technology appraisal guidance
    Published
    27 March 2002

  14. Obinutuzumab for untreated advanced follicular lymphoma (TA513)

    Evidence-based recommendations on obinutuzumab (Gazyvaro) for untreated advanced follicular lymphoma in adults.

    Technology appraisal guidance
    Published
    21 March 2018
    View recommendations

    Sections for TA513

  15. Juvenile idiopathic arthritis - abatacept [ID27]

    Discontinued [GID-TAG402]

    Technology appraisal guidance
    Discontinued